ProQR Therapeutics N.V. (NASDAQ:PRQR) went up to recover about 443.57% since recording its record low price of $2.8. The stock experienced 0.13% jump, arriving at $15.22 on 01/17/2019. During the day, the stock price traveled from $15.06 to $15.59. This company shares are 95.4% off its target price of $29.74 and the current market capitalization stands at $555.68M. The recent change has given its price a -14.92% deficit over SMA 50 and -36.58% deficit over its 52-week high. The stock witnessed -14.11% declines, -15.44% declines and 112.87% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PRQR’s volatility during a week at 8.34% and during a month it has been found around 8.51%.ProQR Therapeutics N.V. (PRQR) Top Holders
Institutional investors currently hold around $295 million or 65.2% in PRQR stock. Look at its top three institutional owners. Rtw Investments, Lp owns $56.84 million in ProQR Therapeutics N.V., which represents roughly 10.23% of the company’s market cap and approximately 19.27% of the institutional ownership. Similar statistics are true for the second largest owner, Adage Capital Partners Gp, L.L.C., which owns 3,461,941 shares of the stock are valued at $52.62 million. The third largest holder is Jennison Associates Llc, which currently holds $45.57 million worth of this stock and that ownership represents nearly 8.2% of its market capitalization.ProQR Therapeutics N.V. 13F Filings
At the end of September reporting period, 22 institutional holders increased their position in ProQR Therapeutics N.V. (NASDAQ:PRQR) by some 9,453,007 shares, 14 decreased positions by 1,116,226 and 3 held positions by 8,837,334. That puts total institutional holdings at 19,406,567 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 6,582,833 shares while 4 institutional investors sold out their entire positions totaling 426,636 shares.ProQR Therapeutics N.V. (PRQR) Analyst Guide
Several analysts have released their opinion on ProQR Therapeutics N.V. (NASDAQ:PRQR), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.83 average brokerage recommendation.